Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target
Guggenheim analyst Michael Schmidt reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $28 price target.
Read original at benzingaStocks · News reference
Monte Rosa Therapeutics Q2 EPS $(0.43) Misses $(0.38) Estimate, Sales $8.968M Beat $5.524M Estimate
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.38) by 13.16 percent. This is a 186.67 percent decrease over losses of $(0.15) per
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 11:42 AM
- Checked
- Aug 6, 2026, 11:43 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Monte Rosa Therapeutics Says First Patient Dosed In Modefire-1, Phase 2 Study Evaluating MRT-2359 In Combination With Apalutamide In Patients With mCRPC With AR Mutations
Read original at benzingaJP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27
JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $31 to $27.
Read original at benzingaGuggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and lowers the price target from $35 to $28.
Read original at benzinga